Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Leuprolide | Approved | Phase 4 | 42 | 18 | 50 | 175 | 52 | CA, EU, US | Jan 26, 1989 | 1989-07 |
| Trastuzumab Emtansine | Approved | Phase 4 | 41 | 16 | 31 | 120 | 8 | CA, EU, US | Feb 22, 2013 | 2006-04 |
| Belantamab Mafodotin | Approved | Phase 3 | 41 | 15 | 10 | 61 | 5 | CA, EU, US | Jul 23, 2025 | Jul 29, 2014 |
| Mosunetuzumab | Approved | Phase 3 | 41 | 25 | 5 | 49 | 7 | CA, EU, US | Jun 3, 2022 | Sep 15, 2015 |
| Goserelin | Approved | Phase 4 | 37 | 19 | 71 | 189 | 13 | CA, US | Dec 29, 1989 | 1987-05 |
| Thiotepa | Approved | Phase 4 | 37 | 19 | 22 | 181 | 17 | CA, EU, US | Mar 15, 2010 | 1990-02 |
| Ramucirumab | Approved | Phase 3 | 37 | 16 | 21 | 135 | 14 | CA, EU, US | Apr 21, 2014 | 2005-01 |
| Mitomycin | Approved | Phase 4 | 37 | 22 | 47 | 128 | 12 | CA, US | Oct 22, 1997 | 1991-09 |
| Panitumumab | Approved | Phase 4 | 35 | 23 | 23 | 180 | 10 | CA, EU, US | Sep 27, 2006 | 2000-04 |
| Axitinib | Approved | Phase 3 | 35 | 18 | 10 | 147 | 11 | CA, EU, US | Jan 27, 2012 | 2002-11 |
| Elranatamab | Approved | Phase 4 | 35 | 26 | 6 | 38 | 5 | CA, EU, US | Aug 14, 2023 | Aug 9, 2019 |
| Pegfilgrastim | Approved | Phase 4 | 34 | 19 | 44 | 220 | 27 | CA, EU, US | Jan 31, 2002 | 1999-09 |
| Imatinib | Approved | Phase 4 | 34 | 20 | 38 | 160 | 67 | CA, EU, US | Nov 7, 2001 | Aug 9, 1999 |
| Prednisolone | Approved | Phase 4 | 34 | 18 | 43 | 125 | 8 | US | Nov 10, 1972 | 1992-11 |
| Dabrafenib | Approved | Phase 4 | 34 | 14 | 11 | 113 | 32 | CA, EU, US | May 29, 2013 | Jun 4, 2009 |
| Amivantamab | Approved | Phase 3 | 34 | 15 | 7 | 39 | 15 | CA, EU, US | May 21, 2021 | May 24, 2016 |
| Sunitinib | Approved | Phase 4 | 33 | 14 | 43 | 361 | 39 | CA, EU, US | Jan 26, 2006 | 2003-04 |
| Pegaspargase | Approved | Phase 4 | 33 | 14 | 45 | 125 | 7 | CA, EU, US | Feb 1, 1994 | 1994-07 |
| Talazoparib | Approved | Phase 3 | 33 | 19 | 2 | 94 | 17 | CA, EU, US | Oct 16, 2018 | Jan 3, 2011 |
| Tucatinib | Approved | Phase 4 | 33 | 13 | 6 | 51 | 7 | CA, EU, US | Apr 17, 2020 | Dec 31, 2013 |
| Ivosidenib | Approved | Phase 3 | 33 | 22 | 7 | 44 | 9 | EU, US | Jul 20, 2018 | Mar 1, 2014 |
| Idarubicin | Approved | Phase 4 | 32 | 18 | 50 | 192 | 13 | CA, US | Feb 17, 1997 | 1993-01 |
| Selumetinib | Approved | Phase 3 | 32 | 8 | 7 | 115 | 10 | CA, EU, US | Apr 10, 2020 | 2006-07 |
| Gilteritinib | Approved | Phase 3 | 32 | 25 | 10 | 53 | 4 | CA, EU, US | Nov 28, 2018 | Oct 9, 2013 |
| Dacarbazine | Approved | Phase 4 | 31 | 15 | 52 | 155 | 6 | CA, US | Aug 27, 1998 | 1990-07 |
| Capivasertib | Approved | Phase 3 | 31 | 13 | 9 | 55 | 6 | CA, EU, US | Nov 16, 2023 | Dec 1, 2010 |
| Tafasitamab | Approved | Phase 3 | 31 | 13 | 5 | 47 | 6 | CA, EU, US | Jul 31, 2020 | 2010-09 |
| Talquetamab | Approved | Phase 3 | 31 | 17 | 6 | 35 | 4 | CA, EU, US | Aug 9, 2023 | Dec 16, 2017 |
| Sorafenib | Approved | Phase 4 | 30 | 12 | 78 | 408 | 13 | CA, EU, US | Dec 1, 2005 | 2002-07 |
| Binimetinib | Approved | Phase 3 | 30 | 12 | 5 | 98 | 8 | CA, EU, US | Jun 27, 2018 | Mar 24, 2011 |
| Retifanlimab | Approved | Phase 3 | 30 | 16 | 6 | 64 | 8 | CA, EU, US | Mar 22, 2023 | Feb 27, 2015 |
| Lutetium (177lu) Vipivotide Tetraxetan | Approved | Phase 3 | 30 | 19 | 4 | 41 | 2 | CA, EU | Nov 7, 2022 | 2016-12 |
| Tarlatamab | Approved | Phase 3 | 30 | 18 | 7 | 34 | 5 | CA, EU, US | May 16, 2024 | Dec 26, 2017 |
| Vinblastine | Approved | Phase 4 | 29 | 13 | 48 | 141 | 10 | CA, US | Apr 29, 1987 | 1989-04 |
| Lurbinectedin | Approved | Phase 3 | 29 | 19 | 10 | 56 | 6 | CA, EU, US | Jun 15, 2020 | 2009-03 |
| Belzutifan | Approved | Phase 3 | 29 | 12 | 8 | 34 | 10 | CA, EU, US | Aug 13, 2021 | Nov 17, 2016 |
| Bicalutamide | Approved | Phase 4 | 27 | 11 | 42 | 134 | 28 | CA, US | Oct 4, 1995 | 1994-12 |
| Crizotinib | Approved | Phase 4 | 27 | 11 | 21 | 90 | 17 | CA, EU, US | Aug 26, 2011 | Mar 7, 2003 |
| Encorafenib | Approved | Phase 3 | 26 | 10 | 6 | 65 | 15 | CA, EU, US | Jun 27, 2018 | Sep 5, 2011 |
| Alectinib | Approved | Phase 4 | 25 | 14 | 12 | 50 | 7 | CA, EU, US | Dec 11, 2015 | Jun 20, 2013 |
| Inotuzumab Ozogamicin | Approved | Phase 4 | 24 | 14 | 6 | 51 | 4 | CA, EU, US | Jun 28, 2017 | 2003-08 |
| Elacestrant | Approved | Phase 3 | 24 | 18 | 5 | 33 | 2 | EU, US | Jan 27, 2023 | 2015-01 |
| Tretinoin | Approved | Phase 4 | 23 | 14 | 23 | 102 | 14 | CA, US | Jan 26, 1973 | 1991-10 |
| Degarelix | Approved | Phase 4 | 23 | 8 | 30 | 97 | 5 | CA, EU, US | Dec 24, 2008 | 2001-03 |
| Cladribine | Approved | Phase 4 | 23 | 17 | 10 | 77 | 5 | CA, EU, US | Apr 14, 2004 | 1994-10 |
| Alpelisib | Approved | Phase 4 | 23 | 6 | 10 | 76 | 12 | CA, EU, US | May 24, 2019 | Oct 5, 2010 |
| Inavolisib | Approved | Phase 3 | 23 | 14 | 5 | 27 | 5 | CA, EU, US | Oct 10, 2024 | Dec 13, 2016 |
| Vorinostat | Approved | Phase 3 | 22 | 5 | 8 | 213 | 3 | CA, US | Oct 6, 2006 | 2000-01 |
| Cobimetinib | Approved | Phase 3 | 22 | 7 | 8 | 85 | 7 | CA, EU, US | Nov 10, 2015 | 2007-05 |
| Sotorasib | Approved | Phase 4 | 21 | 13 | 5 | 42 | 7 | CA, EU, US | May 28, 2021 | Aug 27, 2018 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.